Glem-Lin MXR 25/5/1000mg Tablets (14s) — ideal for online pharmacy product listings, medical catalogs, or e-commerce platforms:
Glem-Lin MXR 25/5/1000mg Tablets (14s) – Triple Oral Therapy for Type 2 Diabetes
Overview:
Glem-Lin MXR 25/5/1000mg is a combination anti-diabetic medication that contains three powerful agents:
-
Empagliflozin 25mg (SGLT2 inhibitor)
-
Linagliptin 5mg (DPP-4 inhibitor)
-
Metformin 1000mg (XR) (biguanide, extended-release)
This triple-action formula is designed to improve glycemic control in adults with type 2 diabetes mellitus (T2DM) who are inadequately managed with diet, exercise, or dual oral therapy alone.
Key Benefits:
-
Empagliflozin reduces blood glucose by increasing urinary glucose excretion
-
Linagliptin enhances insulin secretion and decreases glucagon release
-
Metformin XR reduces hepatic glucose production and improves insulin sensitivity
-
Convenient once-daily dosing with extended-release support
-
Helps with HbA1c reduction, fasting glucose control, and postprandial sugar spikes
Indications:
-
Adults with type 2 diabetes uncontrolled on metformin or dual therapy
-
Patients needing comprehensive glucose control without injections
-
May help reduce cardiovascular risk in eligible patients (due to empagliflozin)
Usage Instructions:
-
Take once daily with food to minimize GI upset
-
Swallow tablet whole; do not crush or chew
-
Dosage adjustment may be required in renal impairment
Precautions:
-
Not for use in type 1 diabetes or diabetic ketoacidosis (DKA)
-
Monitor kidney function and electrolytes regularly
-
May increase risk of genital infections (due to empagliflozin)
Storage:
-
Store below 30°C in a cool, dry place
-
Keep out of reach of child
Glem-Lin MXR 25/5/1000mg – Triple oral therapy (Empagliflozin, Linagliptin,